Holen Sie sich die Stockscreener-App
30.38
0.07%
0.02
Handel nachbörslich:
30.20
-0.18
-0.59%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$30.36
Offen:
$30.57
24-Stunden-Volumen:
1.46M
Relative Volume:
0.81
Marktkapitalisierung:
$4.74B
Einnahmen:
$1.51B
Nettoeinkommen (Verlust:
$333.35M
KGV:
15.58
EPS:
1.95
Netto-Cashflow:
$315.22M
1W Leistung:
+5.60%
1M Leistung:
+3.02%
6M Leistung:
+4.87%
1J Leistung:
+23.55%
1-Tages-Spanne:
$30.18
$30.96
1-Wochen-Bereich:
$28.54
$31.99
52-Wochen-Spanne:
$22.90
$36.45
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Vergleichen Sie ALKS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
30.38 | 4.74B | 1.51B | 333.35M | 315.22M | 1.95 |
|
ZTS
Zoetis Inc
|
155.99 | 69.76B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.06 | 48.12B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.76 | 45.75B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.60 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
306.92 | 13.67B | 2.76B | 1.11B | 898.10M | 22.77 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Alkermes plc (ALKS): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential - Insider Monkey
Alkermes plc (NASDAQ:ALKS) Q1 2025 Earnings Call Transcript - Insider Monkey
Alkermes has near-term catalyst with narcolepsy data, says H.C. Wainwright - TipRanks
BlackRock, Inc. Reduces Stake in Alkermes PLC: A Detailed Analysis - GuruFocus
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Alkermes plc To Contact The Firm - ACCESS Newswire
RBC Capital Raises Price Target for Alkermes (ALKS) to $40 | ALKS Stock News - GuruFocus
Alkermes' Q1 Earnings and Revenues Fall Short of Estimates - Nasdaq
Alkermes (ALKS) Reaffirms 2025 Financial Outlook and Awaits Key Trial Results | ALKS Stock News - GuruFocus
Alkermes (ALKS) Price Target Raised to $41 by Baird Analyst | AL - GuruFocus
Baird Increases Price Target for Alkermes (ALKS) on Promising Ou - GuruFocus
RBC Raises Price Target on Alkermes to $40 From $39, Keeps Sector Perform Rating - marketscreener.com
Alkermes PLC (ALKS) Q1 2025 Earnings Call Highlights: Strong Proprietary Product Growth and ... - Yahoo Finance
Alkermes: Q1 Earnings Snapshot - MySA
Alkermes plc Reports Q1 2025 Financial Results - TipRanks
Alkermes plc Earnings Call Highlights Growth and R&D Progress - TipRanks
Alkermes Plc earnings missed by $0.18, revenue fell short of estimates - Investing.com South Africa
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible (NASDAQ:ALKS) - Seeking Alpha
Chondrosarcoma Market: Epidemiology, Therapies, Companies, - openPR.com
Alkermes to Report First Quarter Financial Results on May 1, 2025 - PR Newswire UK
Alkermes Q1 2025 Earnings Call Transcript - MarketBeat
Here's What Key Metrics Tell Us About Alkermes (ALKS) Q1 Earnings - Yahoo Finance
Alkermes Q1 Earnings, Revenue Decline - marketscreener.com
Alkermes Plc reports results for the quarter ended March 31Earnings Summary - TradingView
Alkermes PLC Q1 2025 Earnings: EPS of $0.13 Beats Estimate, Reve - GuruFocus
Alkermes (ALKS) Misses Q1 Earnings and Revenue Estimates - Yahoo Finance
Alkermes (ALKS) Exceeds Q1 Revenue Expectations and Advances Ore - GuruFocus
Alkermes (ALKS) Exceeds Q1 Revenue Expectations and Advances Orexin 2 Program | ALKS Stock News - GuruFocus
Alkermes plc Reports First Quarter 2025 Financial Results | ALKS Stock News - GuruFocus
Earnings Flash (ALKS) Alkermes Posts Q1 EPS of $0.13, vs. FactSet Est of $0.05 - marketscreener.com
Earnings Flash (ALKS) ALKERMES PLC Reports Q1 Revenue $306.5M, vs. FactSet Est of $302.9M - marketscreener.com
Alkermes plc Reports First Quarter 2025 Financial Results - PR Newswire UK
Do Options Traders Know Something About Alkermes Stock We Don't? - TradingView
Drug Detoxification Market Is Booming Worldwide 2025-2032 | - openPR.com
New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) - PR Newswire
How to Take Advantage of moves in (ALKS) - news.stocktradersdaily.com
UBS Adjusts Alkermes (ALKS) Price Target Amid Softer Q1 Guidance - GuruFocus
Beyond The Numbers: 6 Analysts Discuss Alkermes Stock - Benzinga
UBS Adjusts Alkermes Public Price Target to $33 From $38, Maintains Neutral Rating - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline - Yahoo Finance
U.S. Opioid Withdrawal Treatment Market Emerging Trends - openPR.com
Stocks Update From Health Care Sector -- DexCom, Alkermes, BioCryst Pharmaceuticals, Anacor Pharmaceuticals and Endologix - ADVFN
First Week of June 20th Options Trading For Alkermes (ALKS) - Nasdaq
Alkermes plc's (NASDAQ:ALKS) Earnings Are Not Doing Enough For Some Investors - simplywall.st
Alkermes spinoff Mural plunges on plans to halt ovarian cancer trial - MSN
Alkermes price target raised to $35 from $34 at BofA - MSN
Alkermes to Report First Quarter Financial Results on May 1, 2025 – Company Announcement - Financial Times
Controlled Release Drug Delivery Market Is Booming So Rapidly - openPR.com
Alkermes' CFO Iain Brown passes away - MSN
Alkermes (ALKS) Announces CFO Transition Following Iain M. Brown's Passing - GuruFocus
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
26.29%
23.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):